Search results for "Rash"
showing 10 items of 377 documents
Data-based modeling of vehicle collisions by nonlinear autoregressive model and feedforward neural network
2013
Vehicle crash test is the most direct and common method to assess vehicle crashworthiness. Visual inspection and obtained measurements, such as car acceleration, are used, e.g. to examine impact severity of an occupant or to assess overall car safety. However, those experiments are complex, time-consuming, and expensive. We propose a method to reproduce car kinematics during a collision using nonlinear autoregressive (NAR) model which parameters are estimated by the use of feedforward neural network. NAR model presented in this study is derived from the more general one - nonlinear autoregressive with moving average (NARMA). Suitability of autoregressive systems for data-based modeling was …
Mathematical Modeling and Optimization of a Vehicle Crash Test based on a Single-Mass
2014
In this paper mathematical modelling of a vehicle crash test based on a single mass is studied. The models under consideration consist of a single mass, a spring and/or a damper. They are constructed according to the measured vehicle speed before the collision and measured vehicle accelerations in three directions at the centre of gravity. A new model of nonlinear spring-mass-damper is also proposed to describe the crash. Simulation results are provided to show the effectiveness and applicability of the proposed methods.
A Novel Technique for Modeling Vehicle Crash using Lumped Parameter Models
2021
This paper presents a novel technique for modeling a full frontal vehicle crash. The crash event is divided into two phases; the first until maximum crush and the second part when the vehicle starts pitching forward. This novel technique will help develop a three degrees of freedom (DOF) lumped parameter model (LPM) for crash and support in the vehicle development process. The paper also highlights the design process for reducing vehicle pitching in occupant protection load cases. The model has been validated against a finite element (FE) simulation of a full frontal crash of a Chevrolet Silverado developed by the National Highway Traffic Safety Administration (NHTSA), and the LPM shows goo…
Ultrafast Dynamics of Magnetic Domain Structures Probed by Coherent Free-Electron Laser Light
2013
Synchrotron radiation news 26(6), 27 - 32 (2013). doi:10.1080/08940886.2013.850384
Management of Toxicity Induced by Anti-EGFR Therapy in Metastatic Colorectal Cancer
2013
Use of anti-epidermal growth factor receptor (anti-EGFR) agents has yielded significant advances in the treatment of patients with metastatic colorectal cancer. In fact these drugs, which include the monoclonal antibodies cetuximab and panitumumab, can be delivered both as a single agent and in combination with chemotherapy, achieving better survival and quality of life and in some cases also resectability of metastases. However, these agents can result in the development of toxicities that are usually different from those observed with chemotherapy alone. For the management of these adverse effects, proper knowledge is mandatory. Skin toxicity is the most frequent adverse effect. Other tox…
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma.
2014
Abstract Aim Imgatuzumab (GA201) is a novel anti-epidermal growth factor receptor (anti-EGFR) antibody glycoengineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the efficacy of imgatuzumab in patients with EGFR-positive, KRAS -mutant advanced colorectal cancer. Methods Patients received single-agent imgatuzumab (1400 mg on day 1 and 8 followed by q2W) as third line therapy in an open-label, multicentre, non-randomised, expansion study. The primary end-point was tumour response. Pre- and on-treatment biopsies and blood samples were investigated for biomarkers related to imgatuzumab’s believed mechanism of action (MoA). Results 25 patients were treated…
Quality of Life in Patients With Severe Skin Reactions in Course of First-Generation Epidermal Growth Factor Receptor Inhibitors Monoclonal Antibodie…
2021
Background: Metastatic colorectal cancer (mCRC) with wild type expression of RAS and RAF genes can be treated with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies, such as cetuximab, in combination with chemotherapy. Skin toxicity represents the most serious and frequent side effect in these patients. Skin manifestations occur in approximately 80% of patients. In this study, we investigated the consequences on body image and quality of life (QoL) of patients with severe skin toxicity. Methods: One hundred patients were enrolled with mCRC. All patients signed informed consent and completed questionnaires to assess QoL and body discomfort. Toxicity was assessed on Common Te…
A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and…
2014
e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community…
2011
Background The European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study provided sorafenib to advanced renal cell carcinoma (RCC) patients in whom previous systemic therapy had failed. The study assessed the safety and use of sorafenib for the treatment of advanced RCC in a large community-based patient population across 11 countries in Europe. Patients and methods EU-ARCCS was a single-arm, open-label trial of sorafenib in advanced RCC patients. End points included safety, time to progression, progression-free survival (PFS), and disease control rate (DCR). Subgroup analyses included age, Eastern Cooperative Oncology Group performance status, histology, prior thera…
A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-AKT inhibitor AZD5363 with expansion cohorts in PIK3CA mutant…
2015
Background: AZD5363 is a novel potent pan-AKT inhibitor (IC50of AKT1, AKT2 and AKT3 of 3, 7 and 7nM respectively) with preclinical activity across a range of models. Methods: The trial had an adaptive design that allowed changes in schedule based on toxicity, PK, and PD findings. AZD5363 was administered orally (PO) twice a day (BID). Three schedules were explored: continuous dosing (7/7), four days a week, (4/7) and two days a week (2/7). PD biomarkers including pAKT, pGSK3?, and pPRAS40 were measured by IHC in pre- and post-treatment tumor biopsies. Once a RP2D was established, two expansion cohorts of PIK3CA-mutant ER+ve breast (B) and gynecological (G) cancers were explored. Results: 47…